| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -11,172 | -8,843 |
| Depreciation | 4,054 | 2,663 |
| Amortization of acquisition related intangible assets | 357 | 345 |
| Non-cash operating lease cost | 1,562 | 1,067 |
| Impairment of long-lived assets | 0 | - |
| Stock-based compensation expense | 7,626 | 5,411 |
| Deferred income taxes | 18 | 15 |
| Provision for credit losses | 209 | 133 |
| Provision for inventory | 4,969 | 3,842 |
| Interest income on notes receivable | 424 | 345 |
| Gain on sale of assets | 956 | 505 |
| Accounts receivable | -1,953 | -659 |
| Inventories | -1,809 | -2,252 |
| Prepaid expenses, other current and long-term assets | -1,016 | -797 |
| Accounts payable | -835 | -1,066 |
| Operating lease liabilities | -1,525 | -1,045 |
| Accrued expenses, other current and long-term liabilities | -1,641 | -5,251 |
| Income taxes | -469 | -448 |
| Cash flows from investing activities | 6,551 | -319 |
| Proceeds from sale of parcus | 4,496 | 4,496 |
| Proceeds from sale of intangible assets | 600 | 600 |
| Notes receivable | 483 | 328 |
| Purchases of property and equipment | 6,178 | 4,291 |
| Acquisition of intangible assets | 0 | - |
| Net cash used in investing activities | -599 | 1,133 |
| Proceeds from employee stock purchase program | 261 | 261 |
| Cash paid for tax withheld on vested restricted stock awards | 1,562 | 1,549 |
| Proceeds from exercises of equity awards | 0 | 0 |
| Repurchases of common stock | 3,971 | 3,971 |
| Net cash used in financing activities | -5,272 | -5,259 |
| Exchange rate impact on cash | 151 | 453 |
| Decrease in cash and cash equivalents | 831 | -3,992 |
| Cash and cash equivalents at beginning of period | 57,159 | - |
| Cash and cash equivalents at end of period | 57,990 | - |
Anika Therapeutics, Inc. (ANIK)
Anika Therapeutics, Inc. (ANIK)